5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES
Background: The selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin leads to improved cardiovascular, renal and heart failure outcome in secondary prevention. To better understand these effects, we examined vascular function and central hemodynamics. Methods: In this prospecti...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-12-01
|
| Series: | Artery Research |
| Online Access: | https://www.atlantis-press.com/article/125930220/view |